<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04022949</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-20T23:14:24+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Evaluation of the Care Pathway in the Context of the Dispensing of Emicizumab (Hemlibra) in Community Pharmacies in France: Protocol for a Cross-sectional Study Based on the Kirkpatrick Model</title>
            <author role="aut">
              <persName>
                <forename type="first">Laurie</forename>
                <surname>Fraticelli</surname>
              </persName>
              <email type="md5">d9f09815a93cfd042a69972bf965100f</email>
              <email type="domain">gmail.com</email>
              <idno type="idhal" notation="string">laurie-fraticelli</idno>
              <idno type="idhal" notation="numeric">169569</idno>
              <idno type="halauthorid" notation="string">48175-169569</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-2647-658X</idno>
              <idno type="IDREF">https://www.idref.fr/25312400X</idno>
              <affiliation ref="#struct-526139"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Julie</forename>
                <surname>Freyssenge</surname>
              </persName>
              <idno type="halauthorid">44776-0</idno>
              <affiliation ref="#struct-421734"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Emilie</forename>
                <surname>Promé-Combel</surname>
              </persName>
              <idno type="idhal" notation="numeric">1235792</idno>
              <idno type="halauthorid" notation="string">2752465-1235792</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-8602-4948</idno>
              <affiliation ref="#struct-301764"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Eléonore</forename>
                <surname>Agnellet</surname>
              </persName>
              <idno type="idhal" notation="numeric">1235793</idno>
              <idno type="halauthorid" notation="string">2752466-1235793</idno>
              <idno type="ORCID">https://orcid.org/0000-0003-1888-8063</idno>
              <affiliation ref="#struct-301764"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Yesim</forename>
                <surname>Dargaud</surname>
              </persName>
              <idno type="idhal" notation="numeric">1235794</idno>
              <idno type="halauthorid" notation="string">1447238-1235794</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-4888-1463</idno>
              <affiliation ref="#struct-301764"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Valérie</forename>
                <surname>Chamouard</surname>
              </persName>
              <idno type="idhal" notation="numeric">1235795</idno>
              <idno type="halauthorid" notation="string">718471-1235795</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-4443-1609</idno>
              <affiliation ref="#struct-301764"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Laurie</forename>
                <surname>Fraticelli</surname>
              </persName>
              <email type="md5">d9f09815a93cfd042a69972bf965100f</email>
              <email type="domain">gmail.com</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2023-03-10 10:16:45</date>
              <date type="whenModified">2026-05-05 18:50:01</date>
              <date type="whenReleased">2023-04-04 15:09:51</date>
              <date type="whenProduced">2023-03-08</date>
              <date type="whenEndEmbargoed">2023-03-10</date>
              <ref type="file" target="https://univ-lyon1.hal.science/hal-04022949v1/document">
                <date notBefore="2023-03-10"/>
              </ref>
              <ref type="file" subtype="greenPublisher" n="1" target="https://univ-lyon1.hal.science/hal-04022949v1/file/document.pdf" id="file-4022949-3503899">
                <date notBefore="2023-03-10"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="663946">
                <persName>
                  <forename>Laurie</forename>
                  <surname>Fraticelli</surname>
                </persName>
                <email type="md5">d9f09815a93cfd042a69972bf965100f</email>
                <email type="domain">gmail.com</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04022949</idno>
            <idno type="halUri">https://univ-lyon1.hal.science/hal-04022949</idno>
            <idno type="halBibtex">fraticelli:hal-04022949</idno>
            <idno type="halRefHtml">&lt;i&gt;JMIR Research Protocols&lt;/i&gt;, 2023, 12, pp.e43091. &lt;a target="_blank" href="https://dx.doi.org/10.2196/43091"&gt;&amp;#x27E8;10.2196/43091&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">JMIR Research Protocols, 2023, 12, pp.e43091. &amp;#x27E8;10.2196/43091&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4022949-3503899"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="HCL">Hospices Civils de Lyon</idno>
            <idno type="stamp" n="UNIV-LYON1">Université Claude Bernard - Lyon I</idno>
            <idno type="stamp" n="SANTE_PUB_INSERM" corresp="INSERM">Santé Publique à l'Inserm</idno>
            <idno type="stamp" n="P2S" corresp="UNIV-LYON1">Parcours Santé Systémique - EA 4129</idno>
            <idno type="stamp" n="UDL">UDL</idno>
            <idno type="stamp" n="UNIV-LYON">Université de Lyon</idno>
            <idno type="stamp" n="RESHAPE" corresp="UNIV-LYON1">Unité U1290 RESHAPE (RESearch on HealthcAre PErformance)</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Evaluation of the Care Pathway in the Context of the Dispensing of Emicizumab (Hemlibra) in Community Pharmacies in France: Protocol for a Cross-sectional Study Based on the Kirkpatrick Model</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Laurie</forename>
                    <surname>Fraticelli</surname>
                  </persName>
                  <email type="md5">d9f09815a93cfd042a69972bf965100f</email>
                  <email type="domain">gmail.com</email>
                  <idno type="idhal" notation="string">laurie-fraticelli</idno>
                  <idno type="idhal" notation="numeric">169569</idno>
                  <idno type="halauthorid" notation="string">48175-169569</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-2647-658X</idno>
                  <idno type="IDREF">https://www.idref.fr/25312400X</idno>
                  <affiliation ref="#struct-526139"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Julie</forename>
                    <surname>Freyssenge</surname>
                  </persName>
                  <idno type="halauthorid">44776-0</idno>
                  <affiliation ref="#struct-421734"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Emilie</forename>
                    <surname>Promé-Combel</surname>
                  </persName>
                  <idno type="idhal" notation="numeric">1235792</idno>
                  <idno type="halauthorid" notation="string">2752465-1235792</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-8602-4948</idno>
                  <affiliation ref="#struct-301764"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Eléonore</forename>
                    <surname>Agnellet</surname>
                  </persName>
                  <idno type="idhal" notation="numeric">1235793</idno>
                  <idno type="halauthorid" notation="string">2752466-1235793</idno>
                  <idno type="ORCID">https://orcid.org/0000-0003-1888-8063</idno>
                  <affiliation ref="#struct-301764"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Yesim</forename>
                    <surname>Dargaud</surname>
                  </persName>
                  <idno type="idhal" notation="numeric">1235794</idno>
                  <idno type="halauthorid" notation="string">1447238-1235794</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-4888-1463</idno>
                  <affiliation ref="#struct-301764"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Valérie</forename>
                    <surname>Chamouard</surname>
                  </persName>
                  <idno type="idhal" notation="numeric">1235795</idno>
                  <idno type="halauthorid" notation="string">718471-1235795</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-4443-1609</idno>
                  <affiliation ref="#struct-301764"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">120339</idno>
                <idno type="eissn">1929-0748</idno>
                <title level="j">JMIR Research Protocols</title>
                <imprint>
                  <publisher>JMIR publications</publisher>
                  <biblScope unit="volume">12</biblScope>
                  <biblScope unit="pp">e43091</biblScope>
                  <date type="datePub">2023-03-08</date>
                </imprint>
              </monogr>
              <idno type="doi">10.2196/43091</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en">community health</term>
                <term xml:lang="en">survey</term>
                <term xml:lang="en">questionnaire</term>
                <term xml:lang="en">e-learning</term>
                <term xml:lang="en">e learn</term>
                <term xml:lang="en">cross-sectional</term>
                <term xml:lang="en">learning</term>
                <term xml:lang="en">knowledge acquisition</term>
                <term xml:lang="en">prophylaxis</term>
                <term xml:lang="en">hospital pharma</term>
                <term xml:lang="en">pharmacy</term>
                <term xml:lang="en">hemophilia care pathway healthcare management emicizumab Kirkpatrick model Kirkpatrick emicizumab dispense pharmacy pharmacist pharmaceutic dispensing dispensary dispensation patient satisfaction pharma community pharma community health hospital pharma prophylaxis hemophilia knowledge acquisition learning cross-sectional e learn e-learning questionnaire survey</term>
                <term xml:lang="en">hemophilia</term>
                <term xml:lang="en">care pathway</term>
                <term xml:lang="en">healthcare management</term>
                <term xml:lang="en">emicizumab</term>
                <term xml:lang="en">Kirkpatrick model</term>
                <term xml:lang="en">Kirkpatrick</term>
                <term xml:lang="en">dispense</term>
                <term xml:lang="en">pharmacist</term>
                <term xml:lang="en">pharmaceutic</term>
                <term xml:lang="en">dispensing</term>
                <term xml:lang="en">dispensary</term>
                <term xml:lang="en">dispensation</term>
                <term xml:lang="en">patient satisfaction</term>
                <term xml:lang="en">pharma</term>
                <term xml:lang="en">community pharma</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv.spee">Life Sciences [q-bio]/Santé publique et épidémiologie</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Background Commercialized since 2019, emicizumab (Hemlibra) was available only in French hospital pharmacies for prophylaxis of hemophilia A with or without inhibitors. Since June 15, 2021, patients can choose between a hospital and community pharmacy. These changes in the care pathway have important organizational consequences for patients, their relatives, and health professionals. Two training programs are available for community pharmacists: the “HEMOPHAR” training program proposed by the national reference center for hemophilia and the Roche training program proposed by the laboratory that markets the product. Objective The PASODOBLEDEMI study aims to evaluate the direct impact of the training programs provided to community pharmacists in the context of the dispensing of emicizumab, and to evaluate patients’ satisfaction with their treatment whether they choose dispensation from a community pharmacy or retained dispensation from the hospital pharmacy. Methods We designed a cross-sectional study based on the 4-level Kirkpatrick evaluation model: the immediate reaction of community pharmacists following training (Reaction), the knowledge acquired during the training (Learning), the professional practice of community pharmacists during dispensing of the product (Behavior), and patients’ satisfaction related to the treatment whether it is dispensed from a hospital or from a community pharmacy (Results). Results Considering that single outcome measures cannot adequately reflect the complexity of this new organization, the Kirkpatrick evaluation model provides 4 distinct outcomes: the immediate reaction after the HEMOPHAR training program, the level of knowledge acquired after the HEMOPHAR training program, the impact of training on professional practice, and patient satisfaction with access to emicizumab. We developed specialized questionnaires for each of the 4 levels of the Kirkpatrick evaluation model. All community pharmacists involved in dispensing emicizumab, whether they have followed the HEMOPHAR or the Roche training program or neither, were eligible for inclusion. All patients with severe hemophilia A were eligible, irrespective of inhibitor use, age, treatment with emicizumab, and whether they chose dispensation from a community pharmacy or retained dispensation from a hospital pharmacy. Conclusions The new organization for dispensing emicizumab to patients with hemophilia A in French community pharmacies must be accompanied by optimal safety and quality conditions due to the risk of serious and urgent bleeding situations in the management of rare bleeding diseases. The elaboration of the PASODOBLEDEMI protocol has already a positive impact with the commitment of all health professionals, physicians, hospital and community pharmacists, and the patient community. The results will be disseminated among the French authorities and will enable, if necessary, proposing this access model to other rare diseases. Trial Registration ClinicalTrials.gov NCT05449197, https://clinicaltrials.gov/ct2/show/NCT05449197?term=NCT05449197; ClinicalTrials.gov NCT05450640, https://clinicaltrials.gov/ct2/show/NCT05450640?term=NCT05450640 International Registered Report Identifier (IRRID) DERR1-10.2196/43091</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-526139" status="VALID">
          <idno type="IdRef">198088469</idno>
          <idno type="RNSR">200715373J</idno>
          <orgName>Parcours santé systémique</orgName>
          <orgName type="acronym">P2S</orgName>
          <desc>
            <address>
              <addrLine>Faculté de Médecine Laënnec7-11 rue Guillaume Paradin69372 Lyon cedex 08</addrLine>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation name="EA4129" active="#struct-194495" type="direct"/>
            <relation active="#struct-301088" type="indirect"/>
          </listRelation>
        </org>
        <org type="laboratory" xml:id="struct-421734" status="OLD">
          <idno type="IdRef">203652991</idno>
          <idno type="RNSR">201622306F</idno>
          <orgName>Health Service and Performance Research</orgName>
          <orgName type="acronym">HESPER</orgName>
          <date type="start">2016-01-01</date>
          <date type="end">2020-12-31</date>
          <desc>
            <address>
              <addrLine>Site Lacassagne 162 Avenue Lacassagne69424 Lyon 3e</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.hesper.fr</ref>
          </desc>
          <listRelation>
            <relation name="EA7425" active="#struct-194495" type="direct"/>
            <relation active="#struct-301088" type="indirect"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-301764" status="VALID">
          <orgName>Hôpital Louis Pradel [CHU - HCL]</orgName>
          <desc>
            <address>
              <addrLine>59 Boulevard Pinel69500 Bron</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.chu-lyon.fr/fr/hopital-louis-pradel</ref>
          </desc>
          <listRelation>
            <relation active="#struct-300074" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-194495" status="VALID">
          <idno type="IdRef">026402823</idno>
          <idno type="ISNI">0000000121686185</idno>
          <idno type="ROR">https://ror.org/029brtt94</idno>
          <orgName>Université Claude Bernard Lyon 1</orgName>
          <orgName type="acronym">UCBL</orgName>
          <desc>
            <address>
              <addrLine>43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-lyon1.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-301088" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-301088" status="VALID">
          <idno type="ROR">https://ror.org/01rk35k63</idno>
          <orgName>Université de Lyon</orgName>
          <desc>
            <address>
              <addrLine>92 rue Pasteur - CS 30122, 69361 Lyon Cedex 07</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.universite-lyon.fr/</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-300074" status="VALID">
          <idno type="IdRef">026534657</idno>
          <idno type="ROR">https://ror.org/01502ca60</idno>
          <orgName>Hospices Civils de Lyon</orgName>
          <orgName type="acronym">HCL</orgName>
          <desc>
            <address>
              <addrLine>3 Quai des Célestins69002 Lyon</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.chu-lyon.fr/fr/hospices-civils-de-lyon-hcl</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>